[Importance of clinically prognostic factors in the treatment of advanced ovarian carcinoma].
25 patients with stage III and IV ovarian carcinoma were treated with radical surgery and postoperative chemotherapy. Analysis of the disease-free intervals and the survival rates indicated significant differences related to the stage of the disease. Furthermore patients with minimal residual disease (tumor mass less than 2 cm in diameter) had a far better prognosis than patients with extensive residual disease (greater than 3 cm). No correlation could be demonstrated between histological grading, in vitro proliferation rates, hormone receptor status, type of postoperative chemotherapy and survival rates.
Albrecht
M
M
Goepel
E
E
Simon
W E
WE
Trams
G
G
D000230:Adenocarcinoma / Q000401:mortality / Q000628:therapy*; D002288:Adenocarcinoma, Mucinous / Q000401:mortality / Q000628:therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004715:Endometriosis; D005260:Female; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy*; D010053:Ovary / Q000601:surgery; D010440:Peptichemio / Q000008:administration & dosage; D011379:Prognosis; D011987:Receptors, Steroid
D011987:Receptors, Steroid; D004317:Doxorubicin; D003520:Cyclophosphamide; D010440:Peptichemio
Die Bedeutung klinisch-prognostischer Faktoren für die Behandlung fortgeschrittener Ovarialkarzinome.